u/cagrilintide_enthusiast

Disagree with this specific inference.

This is the sentence the rest of the board should read first. Phase 2 is not a label.

Where the evidence actually stands, since every thread here assumes a different answer.

Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.

Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.

Where the evidence actually stands, since every thread here assumes a different answer.

Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.

Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.

a lot of the confident posting here is extrapolation

Correcting myself upthread: I said the gradient was linear and looking again it has a hold in the middle.

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.

Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.

Small fix — 214nm, not 210. It matters for the comparison you are making with the other run.

Did you run a blank between injections?

wait for phase 3 before you argue about rankings

Area percent is the integrated area of your peak over the total integrated area at one wavelength on one gradient. Change any of those and the number changes without the sample changing.

Not convinced. You are attributing a week of reflux to the glucagon arm when the escalation rate alone would explain it.

That is area percent, not mass percent. The trace cannot give you the second one.

ghost peak, check the plumbing first, it is always the plumbing

Agreed, and the framing that helps is: this is a phase 2 compound with phase 3 running. Everything else is inference.

the criteria change at plan renewal and nobody announces it

special authorization forms are published, read them before applying

Same view — private and provincial plans are genuinely different processes with different appeal routes.

Is that baseline drawn by the software or by hand?

Are you comparing against phase 3 numbers for something else? They are not comparable.

Is that the 48-week figure or an earlier readout?

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

This. A shoulder that does not baseline-resolve is a question, not a quantity.

That is an employer plan process, and the provincial route is different in both form and timeline.

Where the evidence actually stands, since every thread here assumes a different answer.

Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.

Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.

Was this a denied authorization or a rejected claim?

sequence_checker is right that a rejected claim and a denied authorization are different animals.

report the method or do not report the number

Resolution between two peaks depends on retention, selectivity and efficiency. A shallower gradient buys retention and usually resolution, at the cost of peak width and run time.

Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.

How old is the column and roughly how many injections has it seen?

The thing that surprised me was how much of the discussion here is inference rather than measurement.

The standing caveat, written out properly because it keeps getting compressed into a footnote.

Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.

What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.

Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.

research-use-only material is not approved for human use, full stop

Correction: TRIUMPH is the phase 3 programme.

Adding the standing caveat: none of this is approved anywhere and research material is not for human use.

Correction: that is regulatory approval, not coverage. They are separate decisions by separate bodies.

Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.